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increasing inpatient utilization, the latter especially true for His-
panics. CONCLUSION: Although all veterans dramatically
adjusted pharmacy use following the copayment change, ethnic
minorities appeared particularly sensitive to drug costs. Similarly,
while white veterans appeared to reduce psychotropic use with
minimal consequences, minorities experienced substantially
elevated admission risks associated with lower cost-related
adherence. Beneﬁt changes for veterans with chronic conditions
should be implemented cautiously and carefully evaluated. Rec-
onciling budgetary concerns with quality care provision requires
sensitive attention to unique patient groups to ensure equity
while minimizing economic and health disparities.
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OBJECTIVE: To compare clinical characteristics of patients ini-
tiating treatment on duloxetine vs. those initiating on venlafaxine
XR, escitalopram, and ﬂuoxetine over a two year period.
METHODS: Retrospective claims analysis of Pharmetrics
managed care health plan patients initiating on select antidepres-
sants between September 1, 2004 and August 31, 2006. A total
of 798,259 patients were assigned to cohorts based on their most
recent antidepressant prescription. Cochran-Mantel-Haenszel
test was used to test the proportional differences among the
four cohorts. RESULTS: Overall, 72.1% of study patients were
female with a mean age of 44.3 years. Demographic differences
between cohorts were modest. Based on comparison of medical
claims within +/-30 days of initiation on venlafaxine XR, escit-
alopram, and ﬂuoxetine, respectively, duloxetine initiators were
more likely to have visited a mental health specialist (24.2% vs.
18.2%, 18.6%, and 16.5%) and been diagnosed with depression
(29.2% vs. 24.1%, 25.4%, 24.9%). Among the depressed,
duloxetine patients were more frequently diagnosed with major
depressive disorder (MDD) (52.8% vs. 44.3%, 40.5%, and
36.4%) and, among those diagnosed with MDD, were more
frequently diagnosed with recurrent MDD (78.2% vs. 73.8%,
66.2%, and 64.1%). Duloxetine initiators were more frequently
diagnosed with a pain condition (44.8% vs. 27.7%, 27.3%,
and 24.9%) , particularly for back (15.5% vs. 7.5%, 7.0%, and
6.3%) or musculoskeletal pain (28.2% vs. 15.5%, 14.4%. and
13.1%), and were more likely to have been treated previously
with a narcotic analgesic (24.2% vs. 11.1%, 9.8%, and 9.2%)
(p < 0.05 for all reported differences). CONCLUSION: Dulox-
etine patients are more likely to present with more severe depres-
sion diagnoses and pain than patients on other antidepressants.
Case mix adjustments should be made when comparing out-
comes and costs associated with treatment with different antide-
pressants. These ﬁndings are broadly consistent with earlier
analyses of data from the ﬁrst four months following introduc-
tion of duloxetine in the U.S.
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OBJECTIVE: To assess month-by-month changes in clinical
characteristics of patients initiating on duloxetine, a new anti-
depressant, during the ﬁrst two years following its initial avail-
ability in the United States. METHODS: Retrospective claims
analysis of Pharmetrics managed care health plan patients ini-
tiating on duloxetine between September 1, 2004 and August
31, 2006. A total of 102,567 duloxetine initiators were identi-
ﬁed for inclusion in this study. Monthly data series for demo-
graphic and clinical characteristics were created on the basis of
Cymbalta initiation date. Claims within +/-30 days of initiation
were used to identify clinical characteristics. RESULTS: Demo-
graphic patterns of patients initiating on duloxetine remained
stable over the two year period (average monthly percent female
73.0%; average monthly age 47.4 years), as did proportions of
patients with any anxiety (20.7%) or a GAD diagnosis (5.6%).
The average monthly % of patients treated by mental health
specialists trended downward over the ﬁrst 16 months of the
study period (from 32.3% to 23.7%), while the % with a
depression diagnosis trended downward (51.0% to 45.4%) for
the ﬁrst 12 months, before stabilizing thereafter. The % of
patients with a pain diagnosis increased over the ﬁrst three
months (62.4% to 66.6%) and remained stable thereafter. Of
those with a depression diagnosis, the % with an MDD diag-
nosis trended downward (55.8% to 45.8%) for 15 months
before stabilizing, while the % of those with MDD diagnosed
with Recurrent MDD remained stable over the entire study
period (77.8%). CONCLUSION: Demographic characteristics
of patients initiating on duloxetine in the two years following
initial availability in the United States have remained relatively
stable. Clinical characteristics have shown some variation, par-
ticularly over the ﬁrst 12 to 16 months following initial avail-
ability. These trends in utilization have implications for the
selection of appropriate methodologies for developing cohorts
for comparing utilization and costs between new and estab-
lished antidepressant medications.
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OBJECTIVE: There has been a rapid increase in the use of
atypical antipsychotics in pediatric populations over the past few
years. Most of these drugs are unapproved in pediatric popula-
tions. Study objectives were: 1) To identify the trend of new users
of atypical antipsychotics in the Arkansas Medicaid population
under the age of 18 for years 2001 through 2005; 2) to classify
the use of each atypical antipsychotic as evidence-based or not
depending on the diagnoses for which it was prescribed; and 3) to
determine which pediatric patients are more likely to receive an
evidence-based atypical antipsychotic prescription. METHODS:
Study was a retrospective database analysis of Arkansas Medic-
aid for the period from January 2000 to December 2006. Par-
ticipants were the subjects under 18 years of age, with their ﬁrst
atypical antipsychotic prescription claim between 2001 and
2005, with no prior antipsychotic use and having a continuous
two-year Medicaid enrollment. Main outcome measure was the
proportion of study cohort with at least one evidence-based
atypical antipsychotic prescription claim, which was deﬁned as
any use of atypical antipsychotic supported by a clinical study in
the literature. RESULTS: The ﬁnal study cohort was 11,700. The
trend of new pediatric users of atypical antipsychotic therapy
increased from 1482 to 3110 new atypical users from 2001 to
2005. After identifying 86 clinical studies from the literature and
deﬁning the evidence-based use for each atypical antipsychotic, it
was found that 41.32% of the new pediatric users did not have
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any evidence-based conditions. Risperidone had the lowest levels
of non-evidence base use of (30.59%) and aripiprazole had the
highest (77.13%). CONCLUSION: The rate of atypical antipsy-
chotic use in pediatrics has doubled between 2001 and 2005 and
a large proportion of the usage in the Arkansas Medicaid pedi-
atric population is not based on strong clinical evidence.
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OBJECTIVE: Anticholinergic medications (ACH) have clinical
beneﬁts but also impair cognitive function in older adults and
may counteract beneﬁts of cholinesterase inhibitors (CHI) in
Alzheimer’s and other dementias. Prevalence of ACH use and
concomitant ACH and CHI use among Indiana Medicaid
recipients in nursing homes with dementia was determined.
METHODS: A retrospective cross-sectional analysis of Indiana
Medicaid claims and enrollment ﬁles identiﬁed persons 65 y/o or
older with dementia who took CHI anytime in 2004 and were
Medicaid-eligible and in nursing homes continuously in 2004.
Dementia was identiﬁed using 26 ICD-9 diagnosis codes deter-
mined in a prior study as speciﬁc for dementia. To exclude
persons with just a trial of CHI, only persons receiving a second
CHI prescription within 30 days of the end of the indicated
days-supply of a prior CHI prescription were classiﬁed as CHI
users. Only users of drugs identiﬁed in published reports as
having clinically signiﬁcant ACH adverse effects (Level 2) or
markedly ACH adverse effects (Level 3) were classiﬁed as ACH
users. Concomitant use was deﬁned as overlap in periods covered
by CHI and ACH supply. Days of concomitant use and ACH
activity levels also were examined. RESULTS: The sample of
3251 individuals had a mean age of 83 years, was 75% female
and, 89% white. Among these, 1,888, 58.07%, (95%
CI = 56.38–59.77) received an ACH some time during the year
and 1519, 46.72% (95% CI = 45.01–48.44) received an ACH
concomitantly with CHI. Among concomitant users, mean
number of days of concomitant use was 158.96 days (95%
CI = 152.61–165.31) and a majority, 58.13% (95% CI = 55.65–
60.61) received a Level 3 ACH concomitantly with CHI. CON-
CLUSION: Concomitant ACH and CHI use was high among
nursing home residents with dementia. Assessing opportunities
for alternatives might lead to strategies for tackling this thera-
peutic dilemma.
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OBJECTIVE: This study was designed to determine the degree to
which second-generation antipsychotics were used off-label for
patients with bipolar disorder (BPD) and to identify patient
characteristics which were most associated with off-label second-
generation antipsychotic use. METHODS: The multi-state
(PHARMetrics) medical claims database was used to evaluate
105,771 adult patients with a diagnosis of bipolar disorder. The
study period was between 1998–2002. The off-label use of a
second-generation antipsychotic medication was deﬁned as a
patient either receiving olanzapine before March 2000 or any
second-generation antipsychotic, other than olanzapine, during
the entire study period. Olanzapine was differentiated from the
others in its class because it was approved for use in BPD in
2000. Multivariate logistic regression analysis was used to assess
the risk of receiving a drug off-label. RESULTS: Sixty-three
percent of the patients were female, and the mean age was 40.3
years. Eleven percent of patients were on lithium, 25% received
other anticonvulsants, 34% were treated with antidepressants,
and 10.5% (7.1% off-label) took second-generation antipsychot-
ics. A higher risk of off-label use was associated with psychiatry
specialist prescribers (Odds Ratio = 1.52, 95% Conﬁdence Inter-
val 1.44–1.59) and certain comorbidities such as substance
abuse (OR = 1.51, 1.38–1.66), anxiety disorder (OR = 1.20,
1.14–1.26), diabetes mellitus (OR = 1.26, 1.16–1.37), cerebral
vascular disease (OR = 1.26, 1.10–1.45), and hypertension
(OR = 1.12, 1.05–1.20). CONCLUSION: The off-label use of
second-generation antipsychotics in treating BPD was fairly
common from 1998–2002 and their use was associated with
some key clinical factors. Our results add to a growing literature
that relationship links the use of newer antipsychotics with dia-
betes, hypertension, obesity, and cerebral-vascular disease.
PMH73
INITIATION OF ATOMOXETINEVS. STIMULANTS FOR
CHILDRENWITH ADHD IN MEDICAID SETTINGS
Van Brunt D1,Ye W1, Pohl G1,Von Allmen H2
1Eli Lilly and Company, Indianapolis, IN, USA, 2IMS Health, Blue Bell,
PA, USA
OBJECTIVE: To identify factors associated with treatment ini-
tiation of atomoxetine (ATX), stimulants (STIM), or long-acting
stimulants (LA-STIM) in children with ADHD using Medicaid.
METHODS: Data were from the IMS Health LRx Database.
Patients covered by Medicaid age <18 years old were selected if
they initiated treatment with an ADHD medication categorized
as ATX, any STIM, or LA-STIM between January 2005 and
December 2005. Initiation was deﬁned as the ﬁrst use of a
medication preceded by 120 days without a prescription in the
same category. Stepwise logistic regression was used to identify
the factors associated with initiations of ATX vs. STIM or ATX
vs. LA-STIM adjusting for age (0–5 vs. 6–12, 13–17 vs. 6–12),
gender, prior ADHD medications, other concomitant psychiatric
medications, provider specialty, and a number of unique of pre-
vious ADHD medications used. RESULTS: A total of 24,141
patients (68.62% male) most recently initiated treatment with
ATX, 144,451(68.84% male) with STIM, and 129,323 (68.82%
male) with LA-STIM. Increasing age was associated with
increased likelihood of ATX initiation (p < .05) relative to
STIM. Other signiﬁcant factors (all p-value < 0.001) were initia-
tion concomitant with use of antidepressants (OR = 1.29),
antimanics (OR = 1.34), antipsychotics (OR = 1.49), anxiolytics
(OR = 1.69), or anticonvulsants (OR = 1.33). ATX initiation
also became more likely with increasing number of historical
ADHD treatment episodes. Pediatricians were more likely to
prescribe STIM over ATX relative to general psychiatrists
(OR = 0.76). Factors for initiation of ATX vs. LA-STIM were
similar to those for the STIM comparisons. CONCLUSION: The
factors associated with initiation of ATX vs. STIM or ATX vs.
LA-STIM suggest that despite common indications, atomoxetine
and stimulants may be addressing different needs. The ﬁndings
suggest that ATX is preferentially prescribed for patients with
psychiatric comorbidities or potentially complicated treatment
proﬁles.
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